Microbial Fermentation Technology Market by Product Type (Fermentation Equipment, Media & Reagents, Services), by Application (Biopharmaceuticals, Industrial Enzymes, Others), by Microorganism (Bacteria, Yeast, Others), by End User (Biopharmaceutical Manufacturers, CDMOs, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
St. Catharines, Ontario, October 2026 — Vectomat Insights has published a new report titled ‘Microbial Fermentation Technology Market by Product Type, Application, Microorganism, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global Microbial Fermentation Technology market was valued at USD 6,127.4 Mn in 2025 and is projected to reach USD 17,180.1 Mn by 2035, growing at a CAGR of 10.86% during the forecast period 2026–2035, according to Vectomat Insights.
Fermentation equipment is the largest product type at 44.0% of 2025 revenue, yet the tightest part of the market is outsourced capacity: AGC Biologics expects a 50% shortfall in microbial manufacturing volume within five years, and North America already holds 35.0% of global spend as BioMADE builds three government-backed pilot plants.
The Global Microbial Fermentation Technology market reached USD 6,127.4 Mn in 2025 and is projected to hit USD 17,180.1 Mn by 2035, a 10.86% CAGR over 2026–2035, according to Vectomat Insights. North America leads with a 35.0% share, fermentation equipment holds 44.0% of revenue, and Asia Pacific grows fastest as China, India and South Korea add biomanufacturing capacity.
Key Insights Snapshot
| Metric | Value |
|---|---|
| Report Title | Global Microbial Fermentation Technology Market Size, Share, Growth & Forecast By Product Type, Application, Microorganism, and End User, 2026–2035 |
| Base Year Market Size | USD 6,127.4 Mn (2025) |
| Forecast Market Size | USD 17,180.1 Mn (2035) |
| CAGR | 10.86% |
| Forecast Period | 2026–2035 |
| Dominant Region | North America (35.0%) |
| Fastest-Growing Region | Asia Pacific |
| Dominant Segment | Fermentation Equipment (44.0%) |
| Dominant Application | Biopharmaceuticals |
| Report Format | |
| Publisher | Vectomat Insights |
What Biotechnology Leaders Need to Know About the Microbial Fermentation Technology Market
Bioprocess & CMC Heads: Microbial CDMO slots are being booked years out: AGC Biologics is already taking 10,000 L reservations for 2029–2034 at Heidelberg. If your late-phase E. coli or Pichia programme doesn't have committed capacity, you're competing for a pool AGC expects to fall 50% short of demand.
Procurement Directors: Single-use microbial fermenters are moving up from the bench — Thermo Fisher's 5L DynaDrive claims 27% higher productivity than glass. Dual-sourcing media now matters too, with Merck KGaA's USD 11.3 Bn Bio-Techne deal set to reshape the reagent supplier map in 2027.
CDMO Executives: Lonza grew CDMO sales 21.7% in 2025 and says microbial work returned to growth in the second half. The CDMO end-user segment is already worth USD 1,715.7 Mn; the margin opportunity sits in owning the scarce 2,000–20,000 L tier where few open-access plants exist.
Life-Science Investors: Capital is concentrating, not disappearing. Fermentation start-ups raised USD 357 Mn in 2025 against USD 651 Mn in 2024 (GFI), while strategic buyers wrote nine- and ten-figure cheques — Novonesis' EUR 600 Mn India plant and FUJIFILM's GBP 400 Mn Teesside expansion among them.
Food & Ingredient R&D Leaders: Precision-fermented proteins are reaching commercial tanks: Liberation Bioindustries' 600,000 L Richmond, Indiana plant starts production in 2026 with more than half its capacity contracted. Brands that lock offtake early will set the price benchmarks everyone else buys against.
What Is the Microbial Fermentation Technology Market?
Microbial Fermentation Technology refers to the bioreactors, culture media, reagents and contract services used to grow bacteria, yeast and fungi that make insulin, vaccines, enzymes, food proteins and specialty chemicals. Why now? Capacity has become the bottleneck. AGC Biologics puts installed global microbial capacity at roughly 275,000 L and expects demand to outrun it by half within five years, while Washington, Brussels, New Delhi and Seoul are all funding domestic biomanufacturing. That's pulling capital into new plants, from Liberation Bioindustries' 600,000 L site in Indiana to WuXi Biologics' Chengdu facility. Vectomat Insights sizes the market at USD 6,127.4 Mn in 2025.
How Is the Microbial Fermentation Technology Market Segmented?
Fermentation equipment takes the biggest slice, 44.0% of 2025 revenue or USD 2,696.1 Mn, because every new microbial line starts with a fermenter order — from Thermo Fisher's 5L DynaDrive at the bench to GEA's 10,000 L tanks for BFF in the Netherlands. Media & reagents follow at 36.0% and services at 20.0%. Growth is remarkably even: every product line has compounded at roughly 10.9% a year since 2023, with equipment edging ahead at 10.86%. By host, bacteria lead at 52.0%; by end user, biopharmaceutical manufacturers hold 56.0%, and CDMOs are where capacity is tightest.
This report segments the Microbial Fermentation Technology market as follows:
- By Product Type: Fermentation Equipment, Media & Reagents, Services
- By Application: Biopharmaceuticals, Industrial Enzymes, Others
- By Microorganism: Bacteria, Yeast, Others
- By End User: Biopharmaceutical Manufacturers, CDMOs, Academic & Research Institutes
- By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa
Browse the full Microbial Fermentation Technology Market report →
Which Region Leads the Microbial Fermentation Technology Market?
North America leads with a 35.0% share in 2025, worth USD 2,144.6 Mn, and the United States accounts for USD 1,672.8 Mn of it. Federal money matters here: BioMADE is building three pilot plants, and Liberation Bioindustries' 600,000 L Indiana site comes online in 2026. Europe holds 29.0%, led by Germany at USD 515.3 Mn. Asia Pacific, at 26.0%, is the fastest-growing region — South Korea's synthetic-biology law, India's BioE3 biofoundries and China's microbial-protein plants are adding capacity from a lower base, and South Korea's 13.1% CAGR tops every tracked country. Latin America (4.0%), the Middle East (3.0%) and Africa (3.0%) round out demand.
Key Factors Propelling the Microbial Fermentation Technology Market
Microbial CDMO Capacity Crunch — Outsourced microbial capacity is running out. AGC Biologics puts installed global capacity near 275,000 L and expects a 50% volume shortfall within five years.
Government Biomanufacturing Programmes — Governments are paying for fermentation plants. BioMADE is building three U.S. pilot facilities, including a USD 132 Mn site with two 25,000 L fermenters.
Microbially Expressed Biologics Demand — Biologics made in E. coli and Pichia keep winning approvals. Biocon Biologics' Kirsty became the first interchangeable insulin aspart biosimilar in July 2025.
Precision Fermentation Reaching Commercial Scale — Precision fermentation is leaving the pilot plant. Liberation Bioindustries' 600,000 L Indiana site starts production in 2026 with over half its capacity contracted.
So we anticipate a 50% shortage of volume in the market.
(Source: Fierce Biotech (industry interview), December 2025)
Key Headwinds Facing the Microbial Fermentation Technology Market
Scale-Up Capital Intensity — Commercial fermentation plants cost hundreds of millions of dollars. That's too much for venture capital alone, so projects stall until debt and offtake contracts line up.
Mid-Scale and Downstream Capacity Gaps — The right-sized tanks often don't exist. Synonym Bio counts only 9 facilities worldwide at 100,000 L or more, and downstream processing is just as scarce.
Venture Funding Pullback — Fermentation start-ups raised USD 357 Mn in 2025, down from USD 651 Mn in 2024, according to the Good Food Institute.
Despite these challenges, the market is set to grow from USD 6,127.4 Mn in 2025 to USD 17,180.1 Mn by 2035.
What Industry Leaders Are Saying About the Microbial Fermentation Technology Market
What we need above everything is certainty
(Source: FoodNavigator, March 2026)
Partnering with AGC Biologics was a clear choice.
(Source: AGC Biologics press release (BioSpace), May 2026)
We really lack the ability to make stuff in the US, so I think the headline has got to be infrastructure
(Source: FoodNavigator, March 2026)
Report Segmentation & Scope
| Vectomat Insights | Market & Reports — Report Segmentation & Scope | |
|---|---|
| Scope Included in the Study | |
| By Product Type |
|
| By Application |
|
| By Microorganism |
|
| By End User |
|
| Regional Analysis | |
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
| Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com | |
Who Are the Leading Companies in the Microbial Fermentation Technology Market?
Key players operating in the Global Microbial Fermentation Technology market include Sartorius AG (Germany), Thermo Fisher Scientific (U.S.), Merck KGaA (Germany), Cytiva (U.S.), GEA Group (Germany), Evonik Industries (Germany), Lonza Group (Switzerland), FUJIFILM Biotechnologies (Japan), AGC Biologics (U.S.), WuXi Biologics (China), Novonesis (Denmark), dsm-firmenich (Switzerland), Ginkgo Bioworks (U.S.), Liberation Bioindustries (U.S.) and Biocon Biologics (India), among others. Equipment and media vendors compete on single-use scale and supply security. The sharper fight is among CDMOs, where whoever opens microbial capacity first wins multi-year reservations. Captive producers such as Novonesis and Biocon Biologics, meanwhile, keep building their own tanks rather than wait in line.
Microbial Fermentation Technology Market: Latest Industry Moves
July 2025 — Biocon Biologics: FDA approved Kirsty (insulin aspart), the first interchangeable biosimilar to NovoLog, produced by Pichia yeast fermentation.
January 2026 — GEA Group: Contracted to build an integrated precision-fermentation upscaling line with 1,000 L and 10,000 L main fermenters for BFF in Ede, Netherlands.
February 2026 — FUJIFILM Biotechnologies: Opened a GBP 400 Mn expansion at Teesside, U.K., adding 2,000 L and 5,000 L single-use capacity.
May 2026 — AGC Biologics: Selected by Teikoku Seiyaku to develop and manufacture rhMMP-7 drug substance, with cell banking in Heidelberg and GMP production in Chiba.
June 2026 — Merck KGaA: Agreed to acquire Bio-Techne for USD 73 per share, an enterprise value of about USD 11.3 Bn, with closing expected around the turn of 2027.
September 2026 — Novonesis: Announced a EUR 600 Mn industrial enzyme production plant in Patalganga, India.
Frequently Asked Questions
What is the Microbial Fermentation Technology market size and forecast?
The Global Microbial Fermentation Technology market was valued at USD 6,127.4 Mn in 2025 and is forecast to reach USD 17,180.1 Mn by 2035, growing at a 10.86% CAGR during 2026–2035. North America leads with a 35.0% share, fermentation equipment is the largest product type at 44.0% of revenue, and Asia Pacific is the fastest-growing region as China, India and South Korea expand biomanufacturing, according to Vectomat Insights.
Which region dominates the Microbial Fermentation Technology market?
North America dominates with a 35.0% share of 2025 revenue (USD 2,144.6 Mn), led by the United States at USD 1,672.8 Mn, where biologics plants, CDMOs and BioMADE's federally funded pilot network are concentrated. Europe follows at 29.0%, anchored by Germany at USD 515.3 Mn. Asia Pacific, at 26.0%, is the fastest-growing region, with South Korea posting a 13.1% forecast CAGR, per the VMI Microbial Fermentation Technology market report.
What are the key growth drivers of the Microbial Fermentation Technology market?
Four forces drive growth: a microbial CDMO capacity crunch, with AGC Biologics expecting a 50% volume shortfall within five years; government biomanufacturing programmes such as BioMADE, the EU Biotech Act and India's BioE3; steady approvals of microbially expressed biologics like Biocon's Kirsty insulin; and precision fermentation reaching commercial scale at sites such as Liberation Bioindustries' 600,000 L Indiana plant, according to Vectomat Insights.
Who are the leading companies in the Microbial Fermentation Technology market?
Leading companies include Sartorius AG, Thermo Fisher Scientific, Merck KGaA, Cytiva, GEA Group, Evonik Industries, Lonza Group, FUJIFILM Biotechnologies, AGC Biologics, WuXi Biologics, Novonesis, dsm-firmenich, Ginkgo Bioworks, Liberation Bioindustries and Biocon Biologics. Equipment and media vendors compete on single-use scale and supply security, while CDMOs compete for scarce microbial capacity booked years in advance, per the VMI Microbial Fermentation Technology market report.
How is the Microbial Fermentation Technology market segmented?
The market is segmented by Product Type (Fermentation Equipment dominant at 44.0%; Media & Reagents; Services), by Application (Biopharmaceuticals dominant at 46.0%; Industrial Enzymes; Others), by Microorganism (Bacteria dominant at 52.0%; Yeast; Others), by End User (Biopharmaceutical Manufacturers dominant at 56.0%; CDMOs; Academic & Research Institutes), and by Region across all six standard VMI geographies with Middle East and Africa separate, according to Vectomat Insights.
How can I access the full VMI Microbial Fermentation Technology market report?
The full VMI Microbial Fermentation Technology market report is available as a free sample, a full purchase or a custom inquiry through the Vectomat Insights website. It runs to 300+ pages with 96 tables and 68 figures and is delivered as a PDF with an Excel add-on on request. For custom scope, contact sales@vectomatinsights.com, per the VMI Microbial Fermentation Technology market report.
Access the Complete Microbial Fermentation Technology Market Report
300+ pages | Global coverage | PDF | 2026
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is a leading market research company. We create authoritative, data-forward reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organisations but also with the newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is updated constantly in order to fulfil our clients' requirements for prompt and direct online access. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312